Prometic Life Sciences Inc., of Laval, Quebec, said the clinical trial application (CTA) for its antifibrotic lead drug candidate, PBI-4050, in patients suffering from a condition associated with type 2 diabetes and severe multi-organ fibrosis has been cleared by the Medicines and Healthcare Products Regulatory Agency in the U.K.